Liang Hong - Shanghai Pharmaceuticals Independent Non-Executive Director
| S1R Stock | EUR 1.58 0.01 0.63% |
Insider
Liang Hong is Independent Non-Executive Director of Shanghai Pharmaceuticals Holding since 2016.
| Age | 43 |
| Tenure | 8 years |
| Phone | 86 21 6373 0908 |
| Web | https://www.sphchina.com |
Shanghai Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0281 % which means that it generated a profit of $0.0281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1024 %, meaning that it generated $0.1024 on every $100 dollars invested by stockholders. Shanghai Pharmaceuticals' management efficiency ratios could be used to measure how well Shanghai Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrea Frohning | Patterson Companies | 53 | |
| Xiaojuan Li | Sinopharm Group Co | 47 | |
| Christine Sacco | Prestige Consumer Healthcare | 47 | |
| Dave Lardy | Patterson Companies | N/A | |
| Patricia English | Cardinal Health | 43 | |
| Xiuchang Jiang | Sinopharm Group Co | 59 | |
| Stanley Bergman | Henry Schein | 73 | |
| Michelle Greene | Cardinal Health | N/A | |
| Jason Hollar | Cardinal Health | 50 | |
| Kevin Pohlman | Patterson Companies | 59 | |
| Qingming Yu | Sinopharm Group Co | 59 | |
| PharmD Mauch | AmerisourceBergen | 56 | |
| Shivani Kaul | Patterson Companies | N/A | |
| James Cleary | AmerisourceBergen | 60 | |
| Mary Fritz | Prestige Consumer Healthcare | N/A | |
| Michael Ettinger | Henry Schein | 62 | |
| Kevin Barry | Patterson Companies | 45 | |
| Bennett Murphy | AmerisourceBergen | N/A | |
| Shuangjun Xu | Sinopharm Group Co | 54 | |
| Kevin Moran | Cardinal Health | N/A | |
| Steven Paladino | Henry Schein | 66 | |
Management Performance
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 |
Shanghai Pharmaceuticals Leadership Team
Elected by the shareholders, the Shanghai Pharmaceuticals' board of directors comprises two types of representatives: Shanghai Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shanghai. The board's role is to monitor Shanghai Pharmaceuticals' management team and ensure that shareholders' interests are well served. Shanghai Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shanghai Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jun Zhou, Chairman of the Board, Non-Executive Director | ||
| Dawei Liu, Vice President Secretary of the Board | ||
| Haoliang Gu, Vice President | ||
| Liang Hong, Independent Non-Executive Director | ||
| Ying Ke, Director Center | ||
| Yong Zhao, Vice President | ||
| Tao Zhong, Board VP | ||
| Jiangnan Cai, Independent Non-Executive Director | ||
| Man Cho, Pres Director | ||
| Shunjiang Yu, Chief Officer | ||
| Jianyi Mao, Vice President | ||
| Min Zuo, President Executive Director | ||
| Yaohua Zhang, Vice President | ||
| Chaoyang Gu, Independent Non-Executive Director | ||
| Yongzhong Li, Vice President Executive Director | ||
| Jinzhu Chen, Secretary of the Board | ||
| Wenxun Huo, Independent Non-Executive Director | ||
| An Li, Non-Executive Director | ||
| Jinqi Yu, G Mang | ||
| Dawei Ge, Vice Chairman of the Board, Non-Executive Director | ||
| Shui ACS, Joint Sec | ||
| Bo Shen, Chief Financial Officer, Vice President, Executive Director | ||
| Linqiong Dong, Securities Representative |
Shanghai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shanghai Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 8.94 B | |||
| Shares Outstanding | 919.07 M | |||
| Shares Owned By Insiders | 22.00 % | |||
| Shares Owned By Institutions | 32.12 % | |||
| Price To Earning | 6.59 X | |||
| Price To Book | 0.67 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.